A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Phase: PHASE3
Conditions: Dry Eye Disease
Sponsor: Aldeyra Therapeutics, Inc.



Reproxalap Ophthalmic Solution 0.25% 
Clinical Trial Protocol: ADX-102-DED-021 
Sponsor: Aldeyra Therapeutics, Inc. 
Final V4.0 16Aug2022 
Appendix 5: Investigator's Signature 
Protocol Title: 
A Multi-Center, Double-Masked, Randomized, Vehicle­
Controlled, Parallel-Group Clinical Trial Evaluating the Safety 
of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry 
Eye Disease 
Protocol Number: 
ADX-102-DED-021 
Amendment 3 Date: 
16 August 2022 
I agree to implement and conduct the study diligently and in strict compliance with the 
protocol, good clinical practices and all applicable laws and regulations. I agree to 
maintain all information supplied by
 and the sponsor in confidence and, when this 
information is submitted to an Institutional Review Board (IRB), Ethical Review 
Committee (ERC) or another group, it will be submitted with a designation that the 
material is confidential. 
I have read this protocol in its entirety, including the above statement, and I agree to all 
aspects. 
Signed: ______________ _ 
Date: _______ _ 
Name:------- - - ------­
Title: ---- - ----------
Site: --------------- --
Address: ----------------
Phone Number: -------------
Confidential 
Page 76 of76